vs
Side-by-side financial comparison of Bio-Techne (TECH) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $194.8M, roughly 1.5× TOMPKINS FINANCIAL CORP). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs 12.8%, a 36.6% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs -6.4%). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 4.2%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
TECH vs TMP — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $194.8M |
| Net Profit | $38.0M | $96.2M |
| Gross Margin | 64.6% | — |
| Operating Margin | 18.4% | 71.7% |
| Net Margin | 12.8% | 49.4% |
| Revenue YoY | -6.4% | 152.7% |
| Net Profit YoY | 68.3% | 388.9% |
| EPS (diluted) | $0.24 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $295.9M | $194.8M | ||
| Q3 25 | — | $87.4M | ||
| Q2 25 | $317.0M | $82.6M | ||
| Q1 25 | $316.2M | $81.7M | ||
| Q4 24 | $297.0M | $77.1M | ||
| Q3 24 | $289.5M | $76.6M | ||
| Q2 24 | $306.1M | $72.7M | ||
| Q1 24 | $303.4M | $72.8M |
| Q4 25 | $38.0M | $96.2M | ||
| Q3 25 | — | $23.7M | ||
| Q2 25 | $-17.7M | $21.5M | ||
| Q1 25 | $22.6M | $19.7M | ||
| Q4 24 | $34.9M | $19.7M | ||
| Q3 24 | $33.6M | $18.6M | ||
| Q2 24 | $40.6M | $15.7M | ||
| Q1 24 | $49.1M | $16.9M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 62.7% | — | ||
| Q1 25 | 67.9% | — | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | — | ||
| Q2 24 | 66.4% | — | ||
| Q1 24 | 67.4% | — |
| Q4 25 | 18.4% | 71.7% | ||
| Q3 25 | — | 35.6% | ||
| Q2 25 | -7.5% | 34.2% | ||
| Q1 25 | 12.2% | 31.6% | ||
| Q4 24 | 16.0% | 33.4% | ||
| Q3 24 | 13.8% | 32.0% | ||
| Q2 24 | 15.0% | 28.3% | ||
| Q1 24 | 22.1% | 30.4% |
| Q4 25 | 12.8% | 49.4% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | -5.6% | 26.0% | ||
| Q1 25 | 7.1% | 24.1% | ||
| Q4 24 | 11.7% | 25.5% | ||
| Q3 24 | 11.6% | 24.3% | ||
| Q2 24 | 13.3% | 21.6% | ||
| Q1 24 | 16.2% | 23.2% |
| Q4 25 | $0.24 | $6.72 | ||
| Q3 25 | — | $1.65 | ||
| Q2 25 | $-0.11 | $1.50 | ||
| Q1 25 | $0.14 | $1.37 | ||
| Q4 24 | $0.22 | $1.39 | ||
| Q3 24 | $0.21 | $1.30 | ||
| Q2 24 | $0.26 | $1.10 | ||
| Q1 24 | $0.31 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $132.8M |
| Total DebtLower is stronger | $260.0M | — |
| Stockholders' EquityBook value | $2.0B | $938.4M |
| Total Assets | $2.5B | $8.7B |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.9M | $132.8M | ||
| Q3 25 | — | $193.5M | ||
| Q2 25 | $162.2M | $212.6M | ||
| Q1 25 | $140.7M | $193.1M | ||
| Q4 24 | $177.5M | $134.4M | ||
| Q3 24 | $187.5M | $132.3M | ||
| Q2 24 | $152.9M | $70.9M | ||
| Q1 24 | $145.3M | $57.1M |
| Q4 25 | $260.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $346.0M | — | ||
| Q1 25 | $330.0M | — | ||
| Q4 24 | $300.0M | — | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — | ||
| Q1 24 | $389.0M | — |
| Q4 25 | $2.0B | $938.4M | ||
| Q3 25 | — | $788.8M | ||
| Q2 25 | $1.9B | $761.8M | ||
| Q1 25 | $2.0B | $741.4M | ||
| Q4 24 | $2.1B | $713.4M | ||
| Q3 24 | $2.1B | $719.9M | ||
| Q2 24 | $2.1B | $674.6M | ||
| Q1 24 | $2.0B | $667.9M |
| Q4 25 | $2.5B | $8.7B | ||
| Q3 25 | — | $8.5B | ||
| Q2 25 | $2.6B | $8.4B | ||
| Q1 25 | $2.6B | $8.2B | ||
| Q4 24 | $2.7B | $8.1B | ||
| Q3 24 | $2.7B | $8.0B | ||
| Q2 24 | $2.7B | $7.9B | ||
| Q1 24 | $2.7B | $7.8B |
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $38.9M |
| Free Cash FlowOCF − Capex | — | $31.9M |
| FCF MarginFCF / Revenue | — | 16.4% |
| Capex IntensityCapex / Revenue | — | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $38.9M | ||
| Q3 25 | — | $34.9M | ||
| Q2 25 | $98.2M | $18.9M | ||
| Q1 25 | $41.1M | $22.2M | ||
| Q4 24 | $84.3M | $95.0M | ||
| Q3 24 | $63.9M | $21.2M | ||
| Q2 24 | $75.5M | $27.3M | ||
| Q1 24 | $81.0M | $23.2M |
| Q4 25 | — | $31.9M | ||
| Q3 25 | — | $33.9M | ||
| Q2 25 | $93.3M | $18.3M | ||
| Q1 25 | $31.0M | $20.9M | ||
| Q4 24 | $77.5M | $88.8M | ||
| Q3 24 | $54.7M | $18.9M | ||
| Q2 24 | $57.5M | $26.3M | ||
| Q1 24 | $64.5M | $21.9M |
| Q4 25 | — | 16.4% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | 29.4% | 22.1% | ||
| Q1 25 | 9.8% | 25.5% | ||
| Q4 24 | 26.1% | 115.1% | ||
| Q3 24 | 18.9% | 24.7% | ||
| Q2 24 | 18.8% | 36.2% | ||
| Q1 24 | 21.3% | 30.0% |
| Q4 25 | — | 3.6% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | 1.5% | 0.8% | ||
| Q1 25 | 3.2% | 1.7% | ||
| Q4 24 | 2.3% | 8.1% | ||
| Q3 24 | 3.2% | 2.9% | ||
| Q2 24 | 5.9% | 1.3% | ||
| Q1 24 | 5.4% | 1.9% |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | 1.82× | 1.13× | ||
| Q4 24 | 2.42× | 4.82× | ||
| Q3 24 | 1.90× | 1.14× | ||
| Q2 24 | 1.86× | 1.74× | ||
| Q1 24 | 1.65× | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
TMP
Segment breakdown not available.
